Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey

Supplementary materials



Figure S1 Regional distribution of cardiologists' practices in China (N=150). **Notes:** Data were obtained from physician surveys.




Figure S2 Reasons for patients' consultation with a cardiologist (N = 1445). **Notes**: Data obtained from patient record forms. **Abbreviation:** HF, heart failure.

Appendix 1

Patient Record Form

| Section A | |
|---|--|
| Q1. What is the patient's age? years OR \square 90+ | |
| Q2. What is the patient's sex? | |
| Section B | |
| Q2. What is the primary reason for this consultation? (Plea | ise ✓ one) |
| ☐ Diagnosis and/or testing of heart failure symptoms | ☐ Patient scheduled visit due to side effects from heart failure therapy |
| ☐ Routine follow-up / for a repeat prescription | ☐ Incoming referral |
| ☐ Patient scheduled visit due to new or more painful and/or debilitating symptoms | ☐ A reason unrelated to the patient's heart failure condition |
| ☐ Patient scheduled visit because heart failure treatment is not working | ☐ Other |
| Q3. What was the time interval between onset of heart fai | |
| Q4. What was the time interval between first visit and diag | OR Patient consulted a physician immediately gnosis of heart failure? |
| weeks ORmonths ORyears | OR Diagnosis made at first visit/consultation |
| Q5. What was the time interval from diagnosis until first pr | rescribed medication to treat heart failure? |
| weeks ORmonths C | DRyears OR |
| ☐ Initiated immediately at diagnosis ☐ No preso | cribed treatment initiated yet |

| Q8. Please indicate on the grid be | low th | e spec | ialty o | | | | | | | ,1 ⁰ | | | | |
|---|----------|----------------|--|-------------|---|----------|--|----------------|---------|-----------------|---------------|-----------|--------------------|--|
| | | | | | i,Š | , , | dolos | | | | , o | | | |
| | | | | | Catildos | Charles | Sudgot | Anico d | 10 0 M | Q-Kabii | indois. | 18/10/0 | le) | |
| | Š | 2 ^C | 3 the state of the | is no |) b. Mon. | | The Country of the Co | is Color | | | Soll Offi | | Officer Officer | |
| a.HCP who the patient first consulted in relation to heart failure | | | | | | | | | | | | | | |
| b.HCP who first confirmed diagnosis of heart failure | | | | | | | | | | | | | | |
| c.HCP who first initiated treatment specifically for heart failure | | | | | | | | | | | | | | |
| d.Other HCPs who have been involved in treating the patient's heart failure | | | | | | | | | | | | | | |
| e.Number of times patient has consulted each HCP in relation to heart failure in the last 12 months | | | | | | | | | | | | | | |
| Section C Q3b. What is this patient's Ejection Fraction level _ Currently At diagnosis12 months ago ? Q4. What is this patient's current NYHA functional classification and what was it 12 months ago (if applicable) | | | | | | | | | | | | | | |
| | - " | | | | | | Currently | | | | 12 months ago | | | |
| (I) No limitation of physical activit symptoms of heart failure (II) Slight limitation of physical activities | • | | | • | | use | | | | | | | | |
| physical activity results in symp (III) Marked limitation of physical a | otoms of | heart f | failure | | • | <u></u> | | | | | | | | |
| ordinary activity causes sympto (IV) Unable to carry on any physica | oms of h | eart fail | lure | • | | <u>`</u> | | | | | | | | |
| failure, or symptoms of heart f | | | LSympa | JIIIS UI 11 | <u></u> | | | | | | | | | |
| Q5. What is the underlying cause | of this | patier | าt's he | art failı | are? (p | lease ' | ∨ allt | hat ap | ply) | | | | | |
| ☐ Idiopathic | | | Valve d | lisease/p | roblems | ; | | | Hypothy | yroidism | 1 | | | |
| Genetic / familial | | | Conger | nital hear | t defect | | | | Chronic | kidney | disease | | | |
| Coronary Heart Disease / Myocardial in | | | | ibrillatio | n | | | | Alcohol | | ouse | | | |
| Chronic obstructive pulmonary disease | <u> </u> | | Arrhyth | | | | | | Smoking | | | | | |
| Hypertension | | | | | ☐ Hypertension ☐ Venous thromboembolism | | | | | | Obesity | | | |
| Cardiomyopathy | | | | | | | | Chagas disease | | | | | | |
| | | | | | | | | | | | | | | |
| ☐ Myocarditis ☐ Cardiac amyloidosis | | | Diabete | | | | | | | know t | he under | lying cau | ıse | |

Section F

Q1a. Which of the following examinations/tests/scans were conducted for this patient (by any physician) to aid their heart failure diagnosis

Q1b. Which of the following examinations/tests/scans were conducted for this patient (by any physician) in order to monitor their heart failure

Q1c. How many times each examination/test/scan has been conducted/used in the <u>last 12 months</u> in relation to the patient's heart failure

Q1d-f. Please also provide the results for the examinations/tests/scans at the time points indicated (please \checkmark one unit per test)

| Physica | l Examin | ations |
|---------|----------|--------|
|---------|----------|--------|

| nysical Examinatio | a) <u>Diagnose</u> this patient's heart failure | b) Monitor this patients heart failure | c) Number of times tested in the <u>last 12</u> months | | d) Current Value / sign currently present | e) Value at diagnosis / sign present at diagnosis | f) Value 12 months ago / sign present 12 months ago |
|---|---|---|--|---|---|--|--|
| 1. Blood pressure (SYS/DIA) | | | | | /mmHg | / mmHg | / mmHg |
| 2. Heart rate | | | | | bpm | bpm | bpm |
| 3. Exercise test | | | | | ☐ Normal ☐ Abnormal | ☐ Normal ☐ Abnormal | ☐ Normal ☐ Abnormal |
| 4. FEV1 (spirometry) | | | | | % | % | % |
| 5. PEFR (peak flow) | | | | | % | % | % |
| 6. Pulmonary crackles | | | | | Yes No | Yes No | Yes No |
| 7. Jugular Venous Pressure (JVP) | | | | | cm H ₂ 0 | cm H ₂ 0 | cm H ₂ 0 |
| Signs of poor circulation / cold extremities | | | | | Yes No | Yes No | Yes No |
| 9. Pleural effusion | | | | | Yes No | Yes No | Yes No |
| S3 gallop / cardiac murmur | | | | | Yes No | Yes No | Yes No |
| 11. Peripheral hypoperfusion | | | | | Yes No | Yes No | Yes No |
| 12. Mitral regurgitation | | | | | Yes No | Yes No | Yes No |
| 13. Aortic stenosis | | | | | Yes No | Yes No | Yes No |
| 14. Peripheral oedema | | | | | Yes No | Yes No | Yes No |
| 15. Family history | | | | | | | |
| 16. Cognitive status | | | | | | | |
| 17. Other | | | | | - <u></u> | | |
| Blood/Urine Tests | | | | | | | |
| | a) <u>Diagnose</u> this patient's heart failure | b) <u>Monitor</u> this patients heart failure | c) Number of times tested in the <u>last 12</u> <u>months</u> | | d) Current Value (please √ a unit) | e) Value at diagnosis (please √ a unit) | f) Value 12 months ago (please √ a unit) |
| B-type natriuretic peptide (BNP) | | | | | pg/mL ng/L pmol/L | pg/mL ng/L pmol/L | ng/L pmol/L |
| 2. N terminal fragment B-type natriuretic peptide (NT-proBNP) | | | | | pg/mL ng/L pmol/L | ng/L | pg/mL ng/L pmol/L |
| 3. Troponin I or T | | | | | pg/mL □ ng/mL □ pg/mL □ ng/L □ μg/L | | pg/mLpg/mL ng/Lµg/L |
| 4. Hs-Troponin I or T | | | | | □ ng/mL □ pg/mL □ ng/L □ μg/L | ng/mL pg/mL | |
| 5. Total Creatinine Kinase (CK-MB) | | | | | Units/L | Units/L | Units/L |
| | | | | _ | | | |

| | a) <u>Diagnose</u> this patient's heart failure | b) Monitor this patients heart failure | c) Number of times tested in the <u>last 12</u> <u>months</u> | d) Current Value (please √ a unit) | e) Value at diagnosis (please ✓ a unit) | f) Value 12 months ago (please ✓ a unit) |
|---|---|--|--|---------------------------------------|---|--|
| 6. Serum AST Aspartate aminotransferase | | | | IU/L mckat/L | IU/L mckat/L | IU/L mckat/L |
| 7. Serum ALT Alanine aminotransferase | | | | IU/L mckat/L | | |
| 8. Triglycerides | | | | g/dlg/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |
| 9. Fasting glucose | | | | mg/dl g/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |
| 10. HbA1c | | | | % mmol/mol | ──% ☐ mmol/mol | |
| 11. Estimated Glomerular Filtration Rate (eGFR) | | | | mL/min/1.73m ² | mL/min/1.73m ² | mL/min/1.73m² |
| 12. Urine Albumin Creatinine Ratio (ACR) | | | | mg/mmol mg/g mg/24hr | mg/mmol mg/g mg/24hr | mg/mmol mg/g mg/24hr |
| 13. Urine Protein Creatinine Ratio (PCR) | | | | mg/mmol mg/g mg/24hr | mg/mmol mg/g mg/24hr | mg/mmol mg/g mg/24hr |
| 14. Serum creatinine | | | | g/dlg/L μmol/L | □mg/dl □g/L □μmol/L | g/L □ μmol/L |
| 15. Serum potassium | | | | mEq/Lg/L mmol/L | mEq/L g/L mmol/L | g/L mmol/L |
| 16. Sodium | | | | g/L mEq/Lg/L mmol/L | mEq/L g/L mmol/L | g/L ☐ mEq/L ☐ g/L |
| 17. Calcium | | | | mg/dl g/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |
| 18. Thyroid Function | | | | □ Normal □ Abnormal | ☐ Normal ☐ Abnormal | ☐ Normal ☐ Abnormal |
| 19. Haemoglobin | | | | g/dL g/L mmol/L | g/dL g/L mmol/L | g/dL g/L mmol/L |
| 20. Total cholesterol | | | | mg/dl g/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |
| 21. LDL-C | | | | mg/dl g/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |
| 22. HDL-C | | | | mg/dl g/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |

| | a) <u>Diagnose</u> this patient's heart failure | b) <u>Monitor</u> this patients heart failure | c) Number of times tested in the <u>last 12</u> <u>months</u> | d) Current Value (please ✓ a unit) | e) Value at diagnosis (please ✓ a unit) | f) Value 12 months ago (please √ a unit) |
|---|---|---|--|---------------------------------------|---|--|
| 23. Highly sensitive C- reactive protein (Hs -CRP) | | | | mg/L mg/dlnmol/L | mg/L mg/dl | mg/L mg/dl nmol/L |
| 24. Blood urea nitrogen (BUN) | | | | mg/dl g/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |
| 25. Urea nitrogen | | | | mg/dl g/L mmol/L | mg/dl g/L mmol/L | mg/dl g/L mmol/L |
| 26. Platelet count | | | | /μL | | |
| 27. Uric acid | | | | ☐ mg/dL ☐ μmol/L | mg/dL □ μmol/L | mg/dL □ μmol/L |
| 28. Other | | | | | | |
| cans / Investigation | a) <u>Diagnose</u> this patient's heart failure | b) <u>Monitor</u> this patients heart failure | c) Number of times tested in the <u>last 12</u> months | d) Current Value | e) Value at diagnosis | f) Value 12 months ago |
| 1. Echocardiogram | | | | □Normal □Abnormal | □ Normal □ Abnormal | □Normal □Abnormal |
| 2. Ejection Fraction | | | | | _ | _ |
| 3. Electrocardiogram (ECG) | | | | □ Normal □ Abnormal | ☐ Normal ☐ Abnormal | ☐ Normal ☐ Abnormal |
| 4. QRS-duration | | | | ms | ms | ms |
| 5. QT- interval | | | | ms | ms | ms |
| 6. Holter monitoring | | | | □Normal □Abnormal | ☐ Normal ☐ Abnormal | □Normal □Abnormal |
| 7. Chest X-ray | | | | □Normal □Abnormal | □ Normal □ Abnormal | □Normal □Abnormal |
| 8. Coronary Angiogram | | | | □Normal □Abnormal | Normal Abnormal | □Normal □Abnormal |
| 9. Cardiac CT scan | | | | □Normal □Abnormal | Normal Abnormal | □Normal □Abnormal |
| 10. Cardiac MRI | | | | □Normal □Abnormal | □ Normal □ Abnormal | □Normal □Abnormal |
| 11. Cardiac catheterization | | | | □Normal □Abnormal | □Normal □Abnormal | □Normal □Abnormal |
| 12. Nuclear medicine scan | | | | □Normal □Abnormal | □ Normal □ Abnormal | □Normal □Abnormal |
| 13. Radionuclide (Isotope) Scan | | | | □Normal □Abnormal | □Normal □Abnormal | □Normal □Abnormal |
| 14. Myocardial scintigraphy | | | | Normal Abnormal | □ Normal □ Abnormal | Normal Abnormal |
| 15. Other | | | | | | |

Section I

Please record all current heart failure therapies, dose per tablet / injection (including unit), frequency, whether it was the patient's initial regimen and duration of treatment. Then work back through any previous regimens recording drug information for each. Please do not include dose change as a change in regimen.

| 1) | | | С | urrent Re | _ | | | | | | Previous Regimen 1 | Previous Regimen 2 | Previous Regimen 3 |
|--------------------------------|--|----------------------|------------------------------------|-------------------|---|-------------------|------------------------------------|--------------|-------------------------------|----------------|--------------------------------|--------------------------------|--------------------------------|
| | pres | urrently scribing | Dose <u>per</u> <u>tablet</u> / | Unit (e.g.) mg | umber times | er ov | Week | Month | Most i dose ti (if appl | itration | | | |
| | No heart failure therapy Benazepril | | injection | | | хГ | ⊐ا∟ ≥ د | ≥ 1□ | ↑□ | √ □ | | | |
| | 3. Captopril | | <u> </u> | | | ` х Г | | ; <u> </u> | <u> </u> | ↓ □ | | | П |
| ORS | 4. Enalapril | | | | ļ | ` <u>.</u> х Г | | ; <u>—</u> . | 1 | ↓ □ | | | |
| 틀 | 5. Fosinopril | | | i | ł | х Г | | ; <u> </u> | ↑□ | <u>↓</u> □ | | | П |
| ACE INHIBITORS | 6. Lisinopril | | | | | x [| 7 | 1— 1— | ↑□ | <u></u> √□ | | | <u></u> |
| Ą | 7. Perindopril | | | | | x 🗆 | | : 10 | ↑□ | <u>↓</u> | | | |
| | 8. Ramipril | | | | | × [| | | Λ□ | √ □ | | | |
| | 9. Candesartan | | | † | | x [| | | ↑□ | $\forall\Box$ | | | |
| ARBs | 10. Losartan | | | | | x [| | | ↑□ | $\forall \Box$ | | | |
| | 11. Valsartan | | | <u> </u> | <u>-</u> | x _ | | | Λ□ | $\forall \Box$ | | | |
| A ERS | 12. Bisoprolol | | | İ | <u> </u> | x [| | | ↑□ | $\forall \Box$ | | | |
| BETA OCKERS | 13. Carvedilol | | <u> </u> | <u> </u> | <u> </u> | x _ | | | ↑□ | $\forall \Box$ | | | |
| <u> </u> | 14. Metoprolol | | | <u> </u> | <u> </u> | × [| | | ↑□ | $\sqrt{\Box}$ | | | |
| STATINS | 15. Atorvastatin | | | <u> </u> | <u> </u> | x [| | | Λ□ | $\forall \Box$ | | | |
| STA | 16. Simvastatin | | | — | <u> </u> | x | | | Λ□ | $\forall \Box$ | | | |
| გ | 17. Apixaban | | | <u> </u> | <u> -</u> | x [| | | ↑□ | V | | | |
| ANTI- COAGULANTS | 18. Dabigatran | | | | <u> </u> | x [| | | Λ□ | $\forall \Box$ | | | |
| Age - | 19. Rivaroxaban | | | <u> </u> | - | x [| | | Λ□ | $\forall \Box$ | | | |
| 8 | 20. Warfarin | | <u> </u> | <u> </u> | <u> - </u> | × [| | | $ \uparrow \Box $ | $\psi\Box$ | | | |
| · | 21. Bumetanide | | | <u> </u> | <u> </u> | x _ | | | $ \uparrow \Box $ | V | | | |
| DIURETICS | 22. Torasemide | <u> </u> | | <u> </u> | <u> </u> | x _ | | | $ \Lambda \Box $ | $\forall \Box$ | <u> </u> | <u> </u> | |
| = - | 23. Furosemide | <u>Ц</u> | | ļ | · | X _ | | | $ \uparrow \Box $ | $\psi\Box$ | | | |
| | 24. Hydroclorothiazide | | | | | × _ | <u> </u> | | $ \uparrow \Box $ | <u> </u> | Ц | | Ш |
| | 25. Spironolactone | Ш | | <u> </u> | <u> </u> | × L | | JШ | ↑□ | $\Psi\Box$ | | Ц | |
| ALDO- STREONE ANTAGONIST | 26. Eplerenone | | — | | - ' | X | | | Λ□ | $\forall \Box$ | | | |
| ∢ | 27. Ivabradine | | <u> </u> | | - | X | | | ↑□ | $\forall \Box$ | | | |
| | 28. Isosorbide dinitrate | | | | _ ; | x [| | | ↑□ | $\forall\Box$ | | | |
| | 29. Digoxin | | | _ | <u> </u> | x [| | | Λ□ | $\Psi\Box$ | | | |
| Please | list below all other heart failure and | cardiovas | cular therap | ¥: | | | | | | | | | |
| | | | | — | _ ; | x [| | | Λ□ | $\forall \Box$ | | | |
| | | | | <u> </u> | <u> </u> ; | x [| | | Λ□ | $\forall \Box$ | | | |
| | | | | | <u> </u> | x [| | | Λ□ | $\forall \Box$ | | | |
| | | | ! | <u> </u> | <u> </u> _ ; | x [| | | Λ□ | $\forall \Box$ | | | |
| | _ | | | | <u> </u> | × [| | | Λ□ | $\psi\Box$ | | | |
| 2) 🗸 if | initial regimen: | | | | | | | | | | | | |
| | vlong has this patient receive gimen for? | d | | _ | M | | (s) C (s) C s) | | | | Week(s) OR Month(s) OR Year(s) | Week(s) OR Month(s) OR Year(s) | Week(s) OR Month(s) OR Year(s) |

For the same regimens recorded on the previous page, please now indicate any issues with the current regimen

| Side effects | |
|--|--|
| 2. Dizziness | |
| 3. Hypotension | |
| 4. Headaches | |
| 5. Confusion / difficulty thinking | |
| 6. Depression | |
| 7. Drowsiness / weakness | |
| 8. Fatigue / Tiredness | |
| 9. Problems sleeping | |
| 10. Gl problems (e.g. diarrhoea/constipation) | |
| 11. Abdominal pain | |
| 12. Stomach problems (e.g. nausea/vomiting) | |
| 13. Loss of appetite | |
| 14. Irregular heartbeat | |
| 15. Joint pain / Muscles aches | |
| 16. Numbness / tingling on skin | |
| 17. Swelling of lips, tongue, throat or face | |
| 18. Abnormal taste (metallic / salty) | |
| 19. Rash | |
| 20. Cough | |
| 21. Blurred vision / Luminous visual phenomena | |
| 22. Cool hands and feet | |
| 23. Increased risk of bleeding | |
| 24. Gout | |
| 25. Sexual dysfunction | |
| 26. Worsening renal function | |
| 27. Hyperkalemia | |

Section J

For each prescribed heart failure therapy the patient is <u>currently receiving</u> please record the following:

- Q1. All reasons which influenced your choice in selecting this patient's current drug(s)
- Q2. Then indicate the most important areas where you feel therapeutic performance could be improved for this patient. These may also have been selected as a reason for choice.

| Please ensure the drugs written in correspond with treatment currently being received | Drug 1 | Drug 2 | Drug 3 | Drug 4 | Drug 5 | 2. Improve- ment areas |
|---|-------------------|-------------------|-------------------|-------------------|-------------------|---------------------------------|
| EFFICACYRELATED | (please write in) | |
| 1. Reduces risk of death | | | | | | |
| 2. Reduces risk of hospitalization | | | | | | |
| 3. Enables good symptom control | | | | | | |
| 4. Improves quality of life | | | | | | |
| 5. Lowers blood pressure | | | | | | |
| 6. Speed of onset of action | | | | | | |
| 7. Long lasting effect | | | | | | |
| 8. Slows progression/worsening of disease | | | | | | |
| 9. Protects renal function | | | | | | |
| 10. Effective across several indications | | | | | | |
| SAFETY RELATED | | | | | | |
| 11. Lack of serious side effects | | | | | | |
| 12. Lower risk of interaction with other drugs | | | | | | |
| 13. Lower risk of causing cough | | | | | | |
| 14. Lower risk of increased potassium levels | | | | | | |
| 15. Good tolerability/long term safe use | | | | | | |
| 16. Lower risk of arrhythmias | | | | | | |
| 17. Low risk of hypotension | | | | | | |
| 18. Less monitoring required | | | | | | |
| 19. Lower risk of renal events | | | | | | |
| 20. Reduces risk of depression | | | | | | |
| 21. Suitable for patients with asthma | | | | | | |
| GENERAL | | | | | | |
| 22. Easy titration | | | | | | |
| 23. Once daily dosing | | | | | | |
| 24. Effective in combination | | | | | | |
| 25. Physician familiarity / experience | | | | | | |
| 26. In accordance with guidelines | | | | | | |
| 27. Patient acceptance / preference to use drug | | | | | | |
| 28. Good trial data / publication evidence | | | | | | |
| 29. Complexity of administrative controls on use | | | | | | |

Section J

| Q4. Thinking about the last treatment decision (initiation, switch, discontinuation) that you made, how | v much |
|---|--------|
| influence did the patient have? | |
| ☐ I made the treatment decision with no discussion | |
| | |
| ☐ We discussed all treatment options together and the patient made the final decision | |
| ☐ The patient asked me to prescribe a specific therapy which I did | |

| c - | | : _ | _ | _ |
|-----|-----|-----|---|---|
| Э: | cti | IO | n | М |

| Q1. How many time none, please write Q2. How many time months? (if none, please comple months (max of 6) | o) nes has this pation please write 0)_ te the grid belo | _times ent been h | nospitalised times | d (as an in | patient) for their | heart fai | lure i | n the l | ast 12 | :hs? <i>(if</i> |
|--|---|-------------------------------------|-----------------------|-------------------|---------------------------------------|------------------|-----------------------|---------|---------------|-----------------|
| Reason for hospitalisation as an inpatient (write in) | | In relation | Туре о | f care? | Procedure /treatment (write in) | Length of | Critical care needed? | | | |
| | Time since hospitalisation | to patients heart failure? | Emergency | Non- emergency | | stay (nights) | Yes | No | Don't know | |
| 1 | days | | | | | | | | | |
| 2 | days | | | | | <u> </u> | | | | |
| 3 | days | | | | | <u> </u> | | | | |
| 4 | days | | | | | | | | | |
| 5 | days | | | | | | | | | |
| 6 | days | | | | | | | | | |
| Q4a. On how man please write 0) | | | | | ent visited the ho | | | | | |
| Q4b. On how mar | - | | | | | - | | | | |

Section Q

Q1 Which of the conditions on the list below did the patient (a) suffer from <u>before being diagnosed</u> with heart failure and (b) start suffering from <u>after being diagnosed</u> with heart failure?

| | 1a) Already suffered before diagnosed with heart failure | 1b) Began suffering after being diagnosed with heart failure |
|--|--|--|
| 1. Anxiety | | |
| 2. Depression | | |
| 3. Migraines / headaches | | |
| 4. Hypertension | | |
| 5. Angina | | |
| 6. Stroke | | |
| | | |
| 7. Hyperlipidaemia | | |
| 8. Deep vein thrombosis | | |
| 9. Peripheral Vascular Disease | | |
| 10. Cerebrovascular Disease | | |
| 11. Long term gastrointestinal problems | | |
| 12. Myocardial infarction | | |
| 13. Obesity | | |
| 14. Cardiac cachexia | | |
| 15. Problems sleeping | | |
| 16. Dementia | | |
| 17. Asthma | | |
| 18. COPD | | |
| 19. Connective Tissue Disease | | |
| 20. Peptic Ulcer Disease | | |
| 21. Diabetes type I (uncomplicated) | | |
| 22. Diabetes type I (with end-organ damage) | | |
| 23. Diabetes type II (uncomplicated) | | |
| | | - |
| 24. Diabetes type II (with end-organ damage)25. Chronic Kidney Disease (mild) | | |
| 26. Chronic Kidney Disease (moderate to | - | |
| severe) | | |
| 27. Hemiplegia | | |
| 28. Leukaemia | | |
| 29. Malignant Lymphoma | | |
| 30. Solid Tumour (metastatic) | | |
| 31. Solid tumour (not metastatic) | | |
| 32. Liver Disease (mild) | | |
| 33. Liver Disease (moderate to severe) | | |
| 34. AIDS | | |
| 35. None | | |
| 36. Other (please | | |
| specify) | | |
| 37. Other (please | | |
| specify) | | |

Patient self-completion form

16. Numbness or tingling on skin

21. Blurred vision / vision problems

22. Cool hands and feet

23. Bleed / bruise easily

25. Sexual dysfunction

19. Rash

24. Gout

26. Other_

20. Coughing

17. Swelling of lips, tongue, throat or face

18. Abnormal taste (metallic or salty taste)

| Section D | | |
|---|------------------------------------|--------------------------------------|
| Q5. Thinking about the last decision that yo | our doctor made about your medic | cine, how much influence did you |
| have? | | |
| ☐ The doctor made the decision about my me | dicine with no discussion | |
| ☐ We discussed all the medicine options toget | - | on |
| ☐ We discussed all the medicine options toget | | |
| ☐ I asked the doctor to prescribe a specific me | dicine which he /she did | |
| Section F | | |
| | | |
| Q1. Please indicate on the grid below which | | suffer from as a result of taking yo |
| currently prescribed heart failure medicine | P(S) | 1 |
| | a) Side effects currently suffered | |
| | (please ✓ all that apply) | |
| I. I am not suffering from any side effects | | |
| 2. Dizziness | | |
| 3. Low blood pressure | | |
| 4. Headaches | | |
| 5. Confusion / difficulty thinking | | |
| 6. Depression | | |
| 7. Drowsiness / weakness | | |
| 8. Fatigue / tiredness | | |
| 9. Problems sleeping | | |
| 10. GI problems (e.g. diarrhoea / constipation) | | |
| 11. Abdominal pain | | |
| 12. Stomach problems (e.g.) Nausea / vomiting | | |
| 13. Loss of appetite | | |
| 14. Irregular heartbeat | | |
| 15 Joint pain / muscle aches | | |

Physician Interview

| Front page | | | |
|----------------------------------|--------------------------|------------------------------|---------|
| Type of Practice ☐ Hospital Only | ☐ Office / Clinic only | ☐ Hospital and office/clinic | ☐ Other |
| If stated hospital s | pecify tier | | |
| ☐ Tier 3 hospital | | | |
| ☐ Tier 2 hospital | | | |
| ☐ Tier 1 hospital☐CHC | | | |
| In which province of | or autonomous region are | vou based? | |